Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.

Vito Di Marco, Vincenza Calvaruso, Alessio Aghemo, Ana Lleo, Massimo Colombo, Alessia M. Giorgini, Pietro Andreone, Maurizia R. Brunetto, Fabio Conti, Vincenzo Boccaccio, Elisabetta Degasperi, Luca Marzi, Erica Villa, Giulia Troshina, Massimo Zuin, Alfredo Di Leo, Andrea Aglitti, Marcello Persico, Barbara Coco, Maria RendinaSimona Bollani, Alessia Ciancio, Patrick Maisonneuve, Pietro Lampertico, Savino Bruno

Risultato della ricerca: Article

8 Citazioni (Scopus)

Abstract

Background: Despite the dramatic improvement in viral eradication rates that has been reached withdirect antiviral agents (DAAs),the real benefit of viral eradication after DAAs on hepatocellular carcinoma(HCC) development is still controversial.Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAAtreated HCV-cirrhotic patients and to identify potential predictors of HCC development.Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhoticpatients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy andfollowed-up for one year after therapy. 161 patients had a previous HCC.Results: 38/161 subjects developed tumor recurrence during the follow-up (recurrence rate = 24.8 per100-year), patients with SVR had a significantly lower rate of recurrence. Lack of SVR and alphafetoprotein (AFP) were independent predictors of HCC recurrence. 50/1766 patients without a previousHCC history developed HCC during follow-up (incidence rate = 2.4 per 100-year). Lack of SVR was thestrongest predictor of HCC development. Furthermore, patients with SVR and no stigmata of portalhypertension have a lower incidence rate of HCC (1.0 per 100-year).Conclusions: SVR is associated with a significant decrease of recurrent or de novo HCC. Baseline AFP andsigns of portal hypertension can help to stratify the risk of HCC.© 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved
Lingua originaleEnglish
pagine (da-a)310-317
Numero di pagine8
RivistaDigestive and Liver Disease
Volume51
Stato di pubblicazionePublished - 2018

Fingerprint

Antiviral Agents
Hepatocellular Carcinoma
Recurrence
Christianity
Incidence
Portal Hypertension
Italy
History
Liver

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cita questo

Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. / Di Marco, Vito; Calvaruso, Vincenza; Aghemo, Alessio; Lleo, Ana; Colombo, Massimo; Giorgini, Alessia M.; Andreone, Pietro; Brunetto, Maurizia R.; Conti, Fabio; Boccaccio, Vincenzo; Degasperi, Elisabetta; Marzi, Luca; Villa, Erica; Troshina, Giulia; Zuin, Massimo; Di Leo, Alfredo; Aglitti, Andrea; Persico, Marcello; Coco, Barbara; Rendina, Maria; Bollani, Simona; Ciancio, Alessia; Maisonneuve, Patrick; Lampertico, Pietro; Bruno, Savino.

In: Digestive and Liver Disease, Vol. 51, 2018, pag. 310-317.

Risultato della ricerca: Article

Di Marco, V, Calvaruso, V, Aghemo, A, Lleo, A, Colombo, M, Giorgini, AM, Andreone, P, Brunetto, MR, Conti, F, Boccaccio, V, Degasperi, E, Marzi, L, Villa, E, Troshina, G, Zuin, M, Di Leo, A, Aglitti, A, Persico, M, Coco, B, Rendina, M, Bollani, S, Ciancio, A, Maisonneuve, P, Lampertico, P & Bruno, S 2018, 'Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.', Digestive and Liver Disease, vol. 51, pagg. 310-317.
Di Marco, Vito ; Calvaruso, Vincenza ; Aghemo, Alessio ; Lleo, Ana ; Colombo, Massimo ; Giorgini, Alessia M. ; Andreone, Pietro ; Brunetto, Maurizia R. ; Conti, Fabio ; Boccaccio, Vincenzo ; Degasperi, Elisabetta ; Marzi, Luca ; Villa, Erica ; Troshina, Giulia ; Zuin, Massimo ; Di Leo, Alfredo ; Aglitti, Andrea ; Persico, Marcello ; Coco, Barbara ; Rendina, Maria ; Bollani, Simona ; Ciancio, Alessia ; Maisonneuve, Patrick ; Lampertico, Pietro ; Bruno, Savino. / Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. In: Digestive and Liver Disease. 2018 ; Vol. 51. pagg. 310-317.
@article{f47461f3dac24deb8d82a34410a549d3,
title = "Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.",
abstract = "Background: Despite the dramatic improvement in viral eradication rates that has been reached withdirect antiviral agents (DAAs),the real benefit of viral eradication after DAAs on hepatocellular carcinoma(HCC) development is still controversial.Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAAtreated HCV-cirrhotic patients and to identify potential predictors of HCC development.Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhoticpatients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy andfollowed-up for one year after therapy. 161 patients had a previous HCC.Results: 38/161 subjects developed tumor recurrence during the follow-up (recurrence rate = 24.8 per100-year), patients with SVR had a significantly lower rate of recurrence. Lack of SVR and alphafetoprotein (AFP) were independent predictors of HCC recurrence. 50/1766 patients without a previousHCC history developed HCC during follow-up (incidence rate = 2.4 per 100-year). Lack of SVR was thestrongest predictor of HCC development. Furthermore, patients with SVR and no stigmata of portalhypertension have a lower incidence rate of HCC (1.0 per 100-year).Conclusions: SVR is associated with a significant decrease of recurrent or de novo HCC. Baseline AFP andsigns of portal hypertension can help to stratify the risk of HCC.{\circledC} 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved",
author = "{Di Marco}, Vito and Vincenza Calvaruso and Alessio Aghemo and Ana Lleo and Massimo Colombo and Giorgini, {Alessia M.} and Pietro Andreone and Brunetto, {Maurizia R.} and Fabio Conti and Vincenzo Boccaccio and Elisabetta Degasperi and Luca Marzi and Erica Villa and Giulia Troshina and Massimo Zuin and {Di Leo}, Alfredo and Andrea Aglitti and Marcello Persico and Barbara Coco and Maria Rendina and Simona Bollani and Alessia Ciancio and Patrick Maisonneuve and Pietro Lampertico and Savino Bruno",
year = "2018",
language = "English",
volume = "51",
pages = "310--317",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",

}

TY - JOUR

T1 - Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.

AU - Di Marco, Vito

AU - Calvaruso, Vincenza

AU - Aghemo, Alessio

AU - Lleo, Ana

AU - Colombo, Massimo

AU - Giorgini, Alessia M.

AU - Andreone, Pietro

AU - Brunetto, Maurizia R.

AU - Conti, Fabio

AU - Boccaccio, Vincenzo

AU - Degasperi, Elisabetta

AU - Marzi, Luca

AU - Villa, Erica

AU - Troshina, Giulia

AU - Zuin, Massimo

AU - Di Leo, Alfredo

AU - Aglitti, Andrea

AU - Persico, Marcello

AU - Coco, Barbara

AU - Rendina, Maria

AU - Bollani, Simona

AU - Ciancio, Alessia

AU - Maisonneuve, Patrick

AU - Lampertico, Pietro

AU - Bruno, Savino

PY - 2018

Y1 - 2018

N2 - Background: Despite the dramatic improvement in viral eradication rates that has been reached withdirect antiviral agents (DAAs),the real benefit of viral eradication after DAAs on hepatocellular carcinoma(HCC) development is still controversial.Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAAtreated HCV-cirrhotic patients and to identify potential predictors of HCC development.Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhoticpatients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy andfollowed-up for one year after therapy. 161 patients had a previous HCC.Results: 38/161 subjects developed tumor recurrence during the follow-up (recurrence rate = 24.8 per100-year), patients with SVR had a significantly lower rate of recurrence. Lack of SVR and alphafetoprotein (AFP) were independent predictors of HCC recurrence. 50/1766 patients without a previousHCC history developed HCC during follow-up (incidence rate = 2.4 per 100-year). Lack of SVR was thestrongest predictor of HCC development. Furthermore, patients with SVR and no stigmata of portalhypertension have a lower incidence rate of HCC (1.0 per 100-year).Conclusions: SVR is associated with a significant decrease of recurrent or de novo HCC. Baseline AFP andsigns of portal hypertension can help to stratify the risk of HCC.© 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved

AB - Background: Despite the dramatic improvement in viral eradication rates that has been reached withdirect antiviral agents (DAAs),the real benefit of viral eradication after DAAs on hepatocellular carcinoma(HCC) development is still controversial.Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAAtreated HCV-cirrhotic patients and to identify potential predictors of HCC development.Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhoticpatients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy andfollowed-up for one year after therapy. 161 patients had a previous HCC.Results: 38/161 subjects developed tumor recurrence during the follow-up (recurrence rate = 24.8 per100-year), patients with SVR had a significantly lower rate of recurrence. Lack of SVR and alphafetoprotein (AFP) were independent predictors of HCC recurrence. 50/1766 patients without a previousHCC history developed HCC during follow-up (incidence rate = 2.4 per 100-year). Lack of SVR was thestrongest predictor of HCC development. Furthermore, patients with SVR and no stigmata of portalhypertension have a lower incidence rate of HCC (1.0 per 100-year).Conclusions: SVR is associated with a significant decrease of recurrent or de novo HCC. Baseline AFP andsigns of portal hypertension can help to stratify the risk of HCC.© 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved

UR - http://hdl.handle.net/10447/345353

M3 - Article

VL - 51

SP - 310

EP - 317

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

ER -